Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
10.2337/diabetes.50.2007.S160 64
Sleep matters
De-escalation strategies in HER2positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel
Their value lies in addressing multiple cardiovascular risk factors simultaneouslyglycaemic control, weight reduction, blood pressure lowering, and modest lipid improvementsrather than providing potent lipid-lowering effects alone
US$ 26.60
US$ 21.93
US$ 25.76
US$ 24.15
US$ 25.86
US$ 27.66
US$ 21.79
US$ 20.14
